Codexis, Inc. (0I0X.L)
LSE · USD
$1.27 (-1.51%) as of
Key statistics
- EPS (TTM)
- -0.3180
- 52-week range
- 1.2600 – 4.8700
- Beta
- 2.55
- Revenue (TTM)
- 77.68M
- Profit margin
- -39.55%
- Volume
- 2.79k
About Codexis, Inc.
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
- Headquarters
- Redwood City, CA, United States
- Employees
- 146
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.